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The ORF50 gene of Kaposi’s sarcoma (KS)-associated herpesvirus, or human herpesvirus 8 (KSHV), activates viral
replication and is weakly homologous to the herpesvirus family of R transactivators; therefore, the transcription and
translation events from this region of KSHV are key events in viral reactivation. We demonstrate that ORF50 is expressed in
a bicistronic message after induction of the viral lytic cycle. ORF50 migrated as a series of polypeptides: the major ones as
119 and 101 kDa, respectively. Using 39 rapid amplification of cDNA ends, RT-PCR, and cDNA library screening, we
demonstrate that the major ORF50 transcript also encodes K8. The ORF50/K8 transcript was resistant to cyclohexamide,
whereas the K8 transcript was only partially resistant to cyclohexamide at early timepoints. Both transcripts showed partial
resistance after 12 h of phorbol ester induction. Using a GAL4-ORF50 fusion protein expression vector, we demonstrate that
the transactivation domain of ORF50 resides within a 160-amino-acid region of the carboxyl portion of the ORF. Upstream
regions of both ORF50 and K8 have basal promoter activity in KSHV-infected cells. K8, which had sequence homology to Bzip
proteins, did not activate either promoter. However, both promoters were activated after cotransfection of ORF50 in BCBL-1
cells. © 1999 Academic Press
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1INTRODUCTION
Kaposi’s sarcoma (KS)-associated herpesvirus, or hu-
an herpesvirus 8 (KSHV), is present in .90% of all
orms of KS (Ambroziak et al., 1995; Buonoguuro et al.,
996; Chang et al., 1994; de Lellis et al., 1995; Dupin et al.,
995; Ekman et al., 1995; Moore and Chang, 1995). Se-
uencing of KSHV reveals a novel herpes virus homolo-
ous to gamma herpesviruses saimiri and Epstein–Barr
irus (EBV), two viruses that are strongly associated with
alignant transformation (Kieff, 1996; Meinl et al., 1995;
ickinson and Kieff, 1996). The KSHV DNA is recovered
rom all stages of lesions, early as well as at end stage
Aluigi et al., 1996). Active gene expression of the iden-
ified genes has been detected within lesions (Reed et al.,
998; Zhong et al., 1996). KSHV in the peripheral blood of
atients with KS is detectable years before the develop-
ent of overt disease (Moore et al., 1996; Quinlivan et al.,
997; Whitby et al., 1995). In addition, analysis of stored
lood samples revealed that the presence of KSHV in the
lood is a predictor for the subsequent development of
S (Whitby et al., 1995). Low KSHV detection rates in
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436arious samples from control populations have substan-
iated the strong correlation of this virus with KS and
ave suggested a role for this virus in other neoplastic
rocesses (Cesarman and Knowles, 1997).
KSHV genes include those with sequence and func-
ional homology to many cellular genes controlling cell
roliferation (Neipel et al., 1997; Russo et al., 1996; Sarid
t al., 1998). The expression of many of these genes
ccurs predominantly during lytic replication. Studies of
iral gene expression in KS have revealed that latency-
ssociated transcripts are present in the majority of cells
n KS lesions. However, lytic transcripts (those found in
SHV-positive cell lines after induction of viral replica-
ion) are found in a subset of cells (Zhong et al., 1996).
he lytic transcripts are present in the malignant cells
i.e., those with spindle morphology). Productively in-
ected monocytes are also present within KS lesions
Blasig et al., 1997). An elegant study by Orenstein et al.
1997) demonstrated mature herpesvirus virions in
plenic KS lesions within spindle-shaped cells. Thus
eplication is likely to play a role in KSHV pathogenesis.
Virally encoded control mechanisms to which KSHV
eplication is subjected are likely to be complex. EBV
ncodes two immediate-early viral proteins (BZLF1; ZE-
RA; Zta, or Z; and BRLF1, Rta, or R) that regulate initia-
ion of the viral replicative pathway (Kieff, 1996). The
erived amino acid sequence of ORF50 gene has homol-
gy with the EBV lytic switch BRLF1 protein (Russo et al.,
996). The KSHV ORF50 gene product activates lytic
SHV replication (Lukac et al., 1998; Sun et al., 1998). The
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437KSHV ORF50/K8ther members of the gamma herpesvirus group also
ncode proteins that are homologous to the prototype
BV R (Bermudez-Cruz, 1997; Whitehouse et al., 1997).
nitial genomic analysis of these gamma herpesviruses
id not reveal a homolog to the other EBV lytic switch
rotein (Bublot et al., 1992). Recently, identification of a
SHV ORF with sequence homology to Z has been re-
orted (Lin et al., 1999). In this study, we further charac-
erized gene expression in the ORF50/K8 region.
RESULTS
inetics of tetradecanoyl phorbol ester acetate
nduction of ORF50
To examine the kinetics of ORF50 expression, the
atently infected B cell line BCBL-1 was induced with
etradecanoyl phorbol ester acetate (TPA). Twelve hours
fter TPA induction, multiple transcripts were dramati-
ally increased (Fig. 1A) as detected by Northern blot
nalysis using a probe spanning both ORF50 and K8
equences (Fig. 2). The major transcripts were ;4.9,
3.7, and ;1.5 kb. All three transcripts accumulated until
8 h. The accrual of the 4.9- and 3.7-kb transcripts was
hreefold at 24 h and peaked with a sevenfold increase at
8 h (Fig. 1B). The 1.5-kb transcript was increased at 24 h
ith a sixfold accumulation but peaked with a 20-fold
ncrease at 48 h. These results show that transcription in
his region after TPA stimulation is rapid and complex.
To correlate the protein production with the accumu-
ation of ORF50 mRNA, nuclear and cytoplasmic extracts
ere prepared from BCBL-1 cells after treatment with
PA. ORF50 protein was detected by Western blot anal-
sis using a rabbit polyclonal anti-ORF50 antibody
Lukac et al., 1998; gift of D. Ganem). This antibody
ecognized a predominant 119-kDa protein in nuclear
nd cytoplasmic extracts (Fig. 1C). A basal level of the
19-kDa ORF50 protein could be detected in both nuclear
nd cytoplasmic extracts of DMSO-treated cells. After
PA induction, a 101-kDa protein was also detected. A
rogressive increase was seen in both the nuclear
RF50 119- and 101-kDa proteins throughout the TPA
reatment. To determine whether the presence of ORF50
rotein in nuclear extracts was due to contamination
ith cytoplasmic proteins, antibodies (Santa Cruz Bio-
echnology, Inc.) to IkB-a (a strictly cytoplasmic protein;
aeuerle and Baltimore, 1988) did not detect IkB-a in the
uclear extracts (data not shown). The predominant
orms were much larger than the predicted size of 74-kDa
eptide Sort (GCG). Smaller forms (predominantly 89 and
2 kDa) of ORF50 were also present in cytoplasmic
xtracts.
SHV ORF50 is expressed as a bicistronic message,
ncoding K8
Northern blot analysis was performed using poly(A)1NA isolated from TPA-treated BCBL-1 cells to identify hpecific ORF50 and K8 transcripts. An antisense ribo-
robe (Fig. 2) complementary to the 59 end of ORF50
DNA (Sun et al., 1998) hybridized predominantly with the
.7-kb transcript from TPA-treated BCBL-1 cells (Fig. 3A).
n antisense riboprobe from the 59 end of the K8 ORF
etected the 3.7-kb mRNA as well as a 1.5-kb transcript
Fig. 3B).
fficient transcription from the ORF50/K8 region
equires protein synthesis
To characterize these transcripts, we used chemical in-
ibition of translation [cyclohexamide (Cyc)] and herpes-
irus DNA replication [phosphonoacetic acid (PAA)]. The
oading of RNA was normalized by determining the density
f the GAPDH hybridization signal. Densitometry of the
.7-kb transcript revealed a rapid doubling of the amount of
ranscript as early as 1 h after TPA induction. Transcript
ccumulation was steady through 12 h of TPA treatment.
fter this transcript, accrual continued through 48 h with a
aximum 4.5-fold increase. Neither Cyc nor PAA inhibited
he first phase of production. The second phase (12–48 h)
as inhibited by Cyc but not PAA. This characterized the
.7-kb transcript ORF50 as an immediate-early mRNA.
A similar analysis was performed on the 1.5-kb tran-
cript. The kinetics of this transcript showed an early and
late phase of accumulation (before and after 12 h). No
nhibition by PAA was seen. Cyc blunted the first phase
f accumulation as well as preventing the second phase.
he blunting of the earlier phase was in contrast to an
bsence of an effect of Cyc on the 3.7-kb transcript.
To determine the downstream structure of ORF50 tran-
cripts, we performed rapid amplification of cDNA ends
RACE) (Fig. 2). Sequence analysis revealed that the
9RACE product began at the gene specific primer site
74313) and extended to a splice donor site in the K8 ORF
t nucleotide (nt) 75323 (Fig. 4A). The splicing removed a
49-bp intron, but the K8 reading frame was maintained.
second splice removed the region between nt 75838
nd 76433, including the K8.1 translational start site. The
equence terminated at nt 76740 after the poly(A)1 signal
ocated at nt 76714. This was the first identifiable poly(A)1
ignal downstream of ORF50. A poly(A)1 tail was present
t the 39 end of the RACE product (nt 76738).
8 is expressed as two spliced forms and is weakly
omologous with the EBV lytic switch protein Z
We screened a cDNA library to obtain clones that
ould confirm the splicing pattern of the 39 RACE prod-
ct. Four positive clones were isolated by this screen. All
our clones had an identical 39 end (nt 76738), with a
oly(A)1 tail implying an authentic transcript (Fig. 4A).
he poly(A)1 signal used was located 20–25 bp up-
tream from the 39 terminus in all these clones (nt 76714).
he 59 ends were variable (74537, 74862, 75077, and one
ybrid with non-KSHV sequence). The splicing pattern
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439KSHV ORF50/K8ncluded the two splices previously identified in the 39
ACE clone. An additional splice was also present that
roduced a frameshift and extends the K8 ORF for an
dditional 48 amino acids, creating an alternatively
pliced form of K8, K8B. Splicing downstream of K8
emoves the translational start site of the recently de-
cribed K8.1 (Chandran et al., 1998; Raab et al., 1998).
Recognition that K8 was transcribed in concert with
RF50 suggested that it was a homolog of the EBV lytic
witch protein, Z, which has a colinear position in the
BV genome. We used computer alignment programs to
etermine the sequence homology between KSHV K8
nd EBV Z (Blast, Pileup, and Bestfit; GCG). Overall, the
equence homology is very low, and the BLAST retrieval
oftware did not identify homology between EBV Z and
HV K8. However, Bestfit and Pileup programs were
sed to search the K8A and K8B sequences for regions
omologous to identified regions of weak homology
range of identity, 3/16 to 5/18 amino acids) to the Z
ransactivator and Bzip signature (domains activation
nd DNA binding domains, respectively) (Flemington et
l., 1992; Kouzarides et al., 1991) (Fig. 4B). A region
eakly homologous with the activator domain is found in
xon 1 and is present in both K8A and K8B. A second
egion homologous with the Z transactivator domain is
ocated in the third exon of K8B but is not present in K8A.
FIG. 2. Map of primers and probes. (1) Map of the ORF50 region of th
f ORF50 is indicated by the hatched area. (2) Arrows indicate primer
ndicated. Bidirectional bar indicates the random prime labeled probe;
FIG. 1. (A) Northern blot of ORF50 transcripts after induction with TPA
ith the ORF50/K8 random primed probe (top panel) and actin (bottom
efers to cells mock treated with DMSO and harvested at 120 h. Approx
ranscript accumulation. Quantification of the predominant transcripts id
ImageQuant; Molecular Dynamics). The y axis represents the fold inc
evels increase in TPA-activated BCBL-1 cells. Nuclear (N) and cytopla
reatment with DMSO (D) or TPA (T). Equal amounts of total nuclear prot
y SDS–PAGE, and electroblotted onto nitrocellulose filter paper. ORF50 was idbasic amino acid region with homology to Bzip signa-
ure domains as identified in exon 2 (present in both K8A
nd K8B). However, the leucine zipper motif is present
nly in the third exon of K8. The spliced forms of K8 do
ave limited homology with EBV Z functional domains.
To confirm the presence of the spliced transcripts
dentified by 39 RACE and cDNA library screening, RT-
CR was performed with gene-specific primers and RNA
solated from TPA-induced BCBL-1 cells (Fig. 4C). The
rimers used in these experiments were designed to
pan the identified splice sites. The cloned 39 RACE
roduct was used as a positive control. Amplification of
enomic DNA was seen with primers 40 and 49 (product
ize 2351) in the RT2 lane. A 1600-bp product is present
n the RT1 lane, consistent with the predicted spliced
ranscript size of 1611. A second set of primers (46 and
9) was also designed that spanned the entire genomic
RF50 (72633–76664). This time, the genomic DNA prod-
ct (expected size, 4031) was not seen, but a 3300-bp
roduct is seen in the RT1 lanes, consistent with the
redicted spliced bicistronic transcript size of 3291 bp.
RF50 encodes a proline-rich transactivator function
We constructed a fusion protein expression vector
ith ORF50 linked to the yeast GAL4 DNA binding do-
V genome. Genomic ORFs are indicated by filled boxes. The first exon
sed for 39 RACE and RT-PCR. (3) Probes used for Northern blots are
ctional bars indicate riboprobes.
ent. A blot of poly(A)1 RNA from TPA-treated BCBL-1 cells was probed
). Time in hours after induction is indicated above each lane. “Mock”
izes of the major transcripts are indicated at the left. (B) Time of peak
d in the blot shown in panel A was performed using phosphorimaging
and the x axis represents the time after induction. (C) ORF50 protein
) extracts were prepared from BCBL-1 cells after 24, 48, and 72 h of
mg) and cytoplasmic protein (50 mg) were loaded onto wells, separatede KSH
sites utreatm
panel
imate s
entifie
rease,
smic (C
ein (10
entified with a polyclonal rabbit anti-ORF50 antibody (gift of D. Ganem).
f
f
e
440 SEAMAN ET AL.FIG. 3. Northern blot analysis of ORF50 RNA after TPA activation. Total RNA was isolated from BCBL-1 cells treated with TPA, Cyc (CYC), or PAA
or the times indicated above each lane. RNA (10 mg) was electrophoresed and blotted to nylon membrane. The blot was stripped after each of the
ollowing hybridizations: (A) ORF50 riboprobe (complement 72570–72887), (B) K8-59 riboprobe (complement 74810–74930), (C) GAPDH, (D) densitom-
try of 3.7-kb transcript, and (E) densitometry of 1.5-kb transcript (see Fig. 1 legend).
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441KSHV ORF50/K8ain. BCBL-1 cells cotransfected with the construct en-
oding the GAL4-ORF50 fusion protein and a chloram-
henicol acetyltransferase (CAT) reporter gene construct
ith upstream GAL4 binding sites (pGAL4-CAT) had sig-
ificantly increased activity (Fig. 5A) compared with cells
otransfected with vector and pGAL4-CAT. These results
ndicated that the C-terminus of ORF50 contained a
ransactivator domain. Activation was present to a lesser
egree in KSHV-negative cells. To further characterize
he activation domain in ORF50, we constructed a series
f deletion mutants (Fig. 5B). Deletion of amino acids
27–691 (d13) did not reduce activation at all. However,
xtending the deletion to amino acid 526 (d12) com-
letely abolished activation, indicating the amino acid
equences between 526–626 were involved. Amino ac-
ds 548–626 and 524–626 restored activation to 10% and
0%, respectively, of that seen with the GAL4-ORF50
onstruct. The amino acids 450–626 were key to ORF50-
ediated activation.
egions upstream of ORF50 and K8 are responsive to
RF50 but not K8
To determine the regulatory potential of ORF50 in the
ontrol of gene expression in the ORF50/K8 region, ad-
itional transfection studies were performed (Fig. 6). Re-
ions upstream of the ORF50 and K8 start sites were
loned upstream of a CAT reporter gene in both sense
nd antisense orientations (Lin et al., 1999; Sun et al.,
998). CAT expression from these constructs was com-
ared with that from a promoterless construct cotrans-
ected with an expression vector, pcDNA3. In the back-
round of KSHV-1 latently infected cells, both K8 and
RF50 upstream regions had basal promoter activity.
he K8 promoter had threefold activity in either sense or
ntisense orientation, whereas the ORF50 promoter only
ad activity in the sense orientation (.fourfold).
FIG. 3Cotransfection with a CMV expression vector directing aRF50 or K8b expression was also performed. The K8b
onstruct did not produce activation from any of the K8 or
F50 promoter constructs. ORF50 expression produced
marked increase in K8 promoter activity (19-fold). Acti-
ation of the ORF50 promoter was also seen, although
ot to the degree seen with the K8 promoter (12-fold).
he antisense K8 promoter construct also demonstrated
esponsiveness to ORF50 in some experiments, but this
bservation was not a consistent finding.
DISCUSSION
ORF50 has recently been shown to reactivate KSHV
rom latency (Lukac et al., 1998; Sun et al., 1998). Our
esults and those of others (Lin et al., 1999; Lukac et al.,
998; Sun et al., 1998) provide the formal basis for un-
erstanding events that occur in the ORF50 region of
SHV genome after chemical induction. Rapid induction
f complex transcription from the ORF50/K8 region was
een after TPA treatment of a KSHV-infected cell line. A
oncomitant increase in the level of nuclear-associated
RF50 protein was observed after TPA induction. The
olecular masses of the predominant forms of ORF50
re larger than the predicted masses; posttranslational
rocessing is the likely explanation. Phosphorylation
ay provide the extra mass as is the case with Z (Bau-
ann et al., 1998) and R (unpublished data). The smaller
orms may represent translation products from truncated
RNAs. It is likely that the posttranslational modifica-
ions of ORF50 control specific functions of the protein.
RF50/K8 transcription is both sensitive and
esistant to Cyc treatment
At timepoints of 1–12 h, only the 3.7-kb transcript was
esistant to Cyc treatment. This characterized only the
.7-kb transcript as immediate-early type. After 12 h, the
inuedccumulation of both transcripts was sensitive to Cyc.
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443KSHV ORF50/K8his indicates that efficient production of both transcripts
equires protein synthesis and occurs in the early phase
f the lytic cyle. In the BC-1 cells (Sun et al., 1999), even
0 mM Cyc markedly inhibits ORF50 and K8 transcription
t early timepoints. The induction of the ORF50/K8 mes-
age (3.7 kb) is modest (;fivefold) in the BCBL-1 cells
ompared with the marked increase seen by Sun et al.
1999). The BC-1 cell line is inducible with n-butyrate, but
n the absence of induction, this cell line is tightly latent
Sarid et al., 1998). The BCBL-1 cells, on the other hand,
ave an appreciable rate of spontaneous lytic replication
Lennette et al., 1996). The differences in ORF50/K8 tran-
cription may explain in part the different rates of spon-
aneous lytic replication seen in the two cell lines.
unctional domains of ORF50 are colinear to
unctional domains in R
A sequence analysis of ORF50 reveals two weakly
onserved regions at either end of the amino acid se-
uence. The functional domains of EBV R have proved to
e difficult to map (Hardwick et al., 1992). The DNA
inding domain is located in the amino half of the protein
ut is readily disturbed by further deletions. The entire
egion is unlikely to have contact with the DNA recogni-
ion site; instead two or more separate subdomains
ithin the functional domain may be required. Alterna-
ively, the entire region may be required before a com-
licated tertiary structure can hold the contact region
xposed for DNA recognition. The R activation domain is
ery large and complex with two proline-rich and two
cidic domains. Dissection of these regions reveals a
trong transcriptional activator that can function when
ne or more of these regions are absent. Similar
tretches of proline-rich regions occur in the carboxyl
egion of ORF50 (amino acids 385–600). The deletional
nalysis that we performed revealed that the amino ac-
ds centered around amino acid 580 were required be-
ore significant activation was seen. Thus a series of
roline-rich regions in ORF50 encode a complex activa-
ion domain that contribute to ORF50 activation.
Reporter gene assays identified ORF50 and K8 pro-
oter elements capable of increasing transcription two-
old to fourfold in a KSHV-positive cell line. The basal
evel of ORF50 promoter activity was greater than that of
8, suggesting that K8 expression is more tightly regu-
ated in these cells. ORF50 activated both the ORF50 and
he K8 promoter elements. Similarly, EBV R is able to
FIG. 4. (A) Maps of the ORF50 39 RACE product and the cDNA librar
cceptor and donor splice sites are indicated beneath each figure. (B)
cid sequences of the K8 transcripts identified by 39RACE (K8a) and cD
f the EBV Z protein (underlined). Conserved amino acids are indicate
RF50 RT-PCR. Lanes with (1) and without (2) RT are indicated abov
ith cloned 39 RACE product used as a template. Primers used are inhe right.ctivate its own promoter through a nonbinding mecha-
ism (Zalani et al., 1992). Promoters that are much more
trongly activated by the EBV R such as the BMLF1
equire DNA binding (Gruffat et al., 1992). Although no
asal or induced activation was found with the ORF50
romoter in the antisense orientation, the basal CAT
ctivity of the K8 promoter was independent of orienta-
ion. Additionally, K8 promoter in the antisense orienta-
ion was activated by ORF50 in some experiments.
hese observations suggest the presence of an ORF50-
esponsive enhancer element or bidirectional promoter
ocated within this region. ORF50 induced CAT activity
sing the K8 upstream region. The level of activation
een here is quite striking. The EBV R is also capable of
p-regulating Z promoter expression (Holley-Guthrie et
l., 1990; Kenney et al., 1989; Zalani et al., 1996). Addi-
ionally, ORF50 was capable of inducing expression us-
ng sequences 59 to the ORF50 transcription start site.
his is also similar to EBV R, which is capable of induc-
ng activity from its own promoter. EBV Z is a known
ransactivator, but the KSHV K8B product expressed
ownstream of the CMV IE promoter did not induce CAT
ene expression from the ORF50 promoter. However,
his by no means excludes the possibility that K8B is a
ranscriptional activator. The activation may require ad-
itional DNA target sites that were not provided in our
onstructs.
In contrast, differences between EBV and HHV-8 tran-
cripts were detected. Initial characterization of the 39
ACE PCR product and the cDNA clones revealed that
oth ORF50 and K8 coding sequences are present in the
ame transcript. This is analogous to the bicistronic
ranscript encoding EBV R and Z (Manet et al., 1989) Both
BV proteins can be translated from this bicistronic
RNA. In addition, EBV Z is translated from a monocis-
ronic transcript that does not contain R coding se-
uence. The 1.5-kb K8 transcript is analogous to this
ranscript; however, the homologous region in EBV pro-
uces a transcript with a fusion ORF consisting of amino
cids from both R and Z DNA binding domains. This
ranscript has an alternative splicing arrangement and
ncodes a fusion of R and Z (RAZ) (Furnari et al., 1994).
AZ has been shown to repress the function of Z. A
omologous transcript from KSHV was not identified, but
he truncated form of K8 (K8A), which does not include
xon 3, may perform a similar negative regulatory func-
ion. Because the organization of these transcripts is
. ORFs are indicated by filled boxes: ORF50 (gray) and K8 (black). The
ce alignment of the 39 RACE and cDNA library transcripts. The amino
rary screening (K8b) are aligned with the activation and Bzip domains
Leucines in a potential leucine zipper motif are indicated in bold. (C)
nes; H indicates water, and M indicates bp marker. 39 indicates lane
below the figure and molecular mass marker sizes are indicated ony clone
Sequen
NA lib
d ( u ).
e the la
dicated
c
f
a
t
b
i
S
i
tFIG. 5. (A) Transactivation of a minimal promoter construct containing five GAL4 response elements in BCBL-1 cells by gal4-ORF 50. A construct
ontaining five GAL4 response elements upstream of a minimal adenovirus E1B promoter linked to CAT (GAL4-CAT) was cotransfected with the
ollowing plasmids: pGAL4 expresses a protein with the GAL-4 DNA binding domain without a transactivator domain (GAL4), pGAL4-ORF50 expresses
chimerical protein with the GAL-4 DNA binding domain fused to the ORF 50 of HHV8 (ORF50), and for RSV-CAT, Rous sarcoma virus LTR is linked
o CAT. The cell lines used are indicated at the bottom of the figure (BCBL-1, DG75, Jurkat). The y-axis indicates percent acetylation. Fold activation
y pGAL-ORF50 is indicted over each column. The error bars indicate the standard deviation. (B) GAL4-ORF50 deletion mutants. The region included
n each construct is indicated by a box. Numbers refer to amino acids of full-length ORF50. *Stop codon. H indicates HindIII; B, BamHI; K, KpnI; S,
acI; Bs, BstEII; and P, PvuI. (C) Activity of GAL4-ORF50 deletion mutants. The construct used is indicated on the x-axis. Percent acetylation is
ndicated on the y-axis. Fold activation by each construct is indicated over each column. If fold activation is not indicated, the activation was no greater
han the activity seen with the GAL4 vector alone (13).
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445KSHV ORF50/K8omewhat different from that of EBV R and Z mRNAs, it is
empting to speculate that the encoded proteins perform
lternate functions for KSHV. Further experiments will be
equired to determine whether this is a possibility.
We characterized the expression from the ORF50/K8
egion to identify early expression events after KSHV
eactivation. A preliminary description of early events
fter KSHV reactivation may now be attempted. ORF50
nd TPA have both been shown to reactivate KSHV
xpression. Here we show that the region upstream to
he ORF50 coding sequence has basal promoter activity
s well as ORF50-inducible activity. After TPA treatment,
RF50 transcripts are amplified, leading to increased
RF50 protein accumulation. Transfection of ORF50 in-
reases K8 promoter-directed transcription in the context
f KSHV-infected cells. To a lesser degree, ORF50 also
ositively autoregulates its own expression, potentially
mplifying viral reactivation in the absence of intervening
vents. Experiments using chemical inhibition of protein
nd DNA synthesis characterized the ORF50 transcript
s immediate-early mRNA with a second accumulation
hase. The second phase of ORF50 production as well
s the K8 transcription may depend on ORF50 protein
roduction. ORF50 then activates expression from the K8
romoter and, to a lesser extent, from its own promoter.
t present, the functional role of K8 and additional events
ownstream of ORF50 expression are not known. Char-
cterization of cell-type specific functions of ORF50, in-
eractions between ORF50 and K8, and the individual
oles these proteins play in the cascade of replicative
FIG. 5ene expression await further experiments. pMATERIALS AND METHODS
ell lines
Jurkat is a human T cell line, HeLa is human papillo-
avirus-infected cervical carcinoma cell line, DG75 is a
uman B cell line, and BCBL-1 (gift of D. Ganem) (Renne
t al., 1996) is a KSHV-infected human primary effusion
ymphoma cell line. All cells were maintained in RPMI
640 supplemented with 10% FCS, penicillin, and strep-
omycin. Induction of KSHV transcripts was accom-
lished by treating BCBL cells with 20 ng/ml TPA
Sigma).
lasmids
The plasmid pCMV-50 was created by inserting a 2-kb
ragment (72888–74930; gift of Yuan Chang and Patrick
oore) into the BamHI–NotI sites of pcDNA3, producing
SGORF50. ORF5–59 (71596–71613/72572–72590; 59-
ccgggatccatggcgcaagatgacaag GGTAAGAAGCTTCG-
CGGT-39) and ORF50–39 (complement of 72933–72953;
9-cccgctgcatgcggctgtca-39) oligonucleotides were syn-
hesized at the UNC-CH Nucleic Acid Core Facility.
RF50–59 and ORF50–39 were used to PCR amplify the
9 end of the ORF50 cDNA (Sun et al., 1998) with BCBL-1
NA as a template. After amplification, the PCR fragment
as digested with BamHI and inserted into the BamHI
ite of pSGORF50 to obtain pCMV-50. Sequencing was
erformed to confirm that the open reading frame was
aintained.
A K8 expression vector (pCMV-K8) was constructed by
inued—Contlacing full-length K8 cDNA under the transcription con-
t
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446 SEAMAN ET AL.rol of the CMV promoter. A 1000-bp BglII–XbaI (nt 74930–
5323/75471–75563/75645–75838/76432–76738) frag-
ent was isolated from a clone identified by cDNA li-
rary screening. A 120-bp SalI–BglII fragment (74810–
4930) was isolated from 39 RACE clone. This 120-bp
ragment contains the remaining K8 coding sequence.
hese two fragments were inserted into pcDNA3 to pro-
uce the pCMV-K8 construct. The construction was con-
irmed by sequencing.
The promoterless CAT plasmid pGCAT-A (Frebourg
nd Brison, 1988) was used to construct reporter plas-
ids containing putative HHV-8 promoters. A 655-bp
ragment (70934–71589) 59 to the ORF50 transcription
tart site (71560) was PCR amplified from TPA-treated
CBL-1 cells using the primers PORF50–59 (59-cccggatc-
tgtgtctcccgtgggacaaa-39) and PORF50–39 (59-cccggatc-
ggctgcctggacagtattct-39). The PCR product was di-
ested with BamHI and inserted into the BamHI site of
GCAT-A in the sense and antisense orientations to
btain p.50p-CAT and p.anti50p-CAT, respectively. A
57-bp DdeI–Sa1I fragment (74253–74810) from pORF50
FIG. 6. Identification of the ORF50 and K8 promoter regions. BCBL
eporter genes under the control of K8 upstream region in the antisen
egion in the antisense (p.antiORF50p-CAT) or sense (p.ORF50p-CAT)
he expression vector and a promoterless CAT construct.as ligated into the BamHI site of pGCAT-A in the sense fnd antisense orientations to obtain p.K8p-CAT and
.antiK8p-CAT, respectively.
A HindIII fragment (72749–75791) (Russo et al., 1996)
rom pORF50 was inserted into the pSG424 vector (Ma
nd Ptashine, 1987) in frame with the yeast GAL4 DNA
inding domain to yield pGAL-ORF50. The pGAL4-CAT
ontains five GAL4 recognition sites upstream of a min-
mal adenovirus E1b promoter. Deletions in the ORF50
oding sequence were made as follows: pGAL-
RF50-d5 was created with SacI digestion and inframe
eligation, removing nt 73787–74129; pGAL-ORF50-d6
as created with KpnI digestion and inframe religation,
emoving nt 73683–74196; pGAL-ORF50-d7 was created
ith BstEII digestion and out-of-frame religation, remov-
ng nt 73876–74451; and pGAL-ORF50-d8 was created
ith partial ApaI digestion and inframe religation remov-
ng nt 73927–74348. The pGAL-ORF50-d9 was con-
tructed by inserting the BamHI (72888)–BglII (74930)
ragment from pcDNAORF50 into the BamHI–XbaI site of
SG424. The plasmid pGAL-ORF50-d10 was constructed
y inserting the BamHI (72888)–KpnI (73683) fragment
were transfected with vector, pCMV-K8b or pCMV-ORF50, and CAT
nti-K8p-CAT) or sense (p.K8p-CAT) orientation or the upstream ORF50
tion. Fold activity was compared with that seen with cotransfection of-1 cells
se (p.a
orientarom pcDNAORF50 into the BamHI–KpnII site of pSG424.
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447KSHV ORF50/K8he plasmid pGAL-ORF50-d11 was constructed by in-
erting the BamHI (72888)–EcoICRI (73787) fragment
rom pcDNAORF50 into the BamHI–EcoICRI site of
SG424. The plasmid pGAL-ORF50-d12 was constructed
y inserting the BamHI (72888)–KpnI (74196) fragment
rom pcDNAORF50 into the BamHI–KpnII site of pSG424.
he plasmid pGAL-ORF50-d13 was constructed by in-
erting the BamHI (72888)–PvuII (74428) fragment from
cDNAORF50 into the BamHI–EcoICRI site of pSG424.
coICRI is a neoschizomer of SacI and leaves a blunt
nd. All plasmids contained the GAL4 nuclear localiza-
ion domain (Silver et al., 1984). All plasmids were se-
uenced to verify the ligation site, and only the BstEII
eletion produced a frameshift.
orthern blots
Poly(A)1 RNA was extracted using the Ultraspec RNA
solation System (Biotecx) and then running the total RNA
ver an Oligotex mRNA Mini Kit (Qiagen). The RNA was
lectrophoresed and transferred to a nylon membrane.
he blot was baked at 80°C for 1 h, followed by UV
ross-linking. Random primed ORF50 probe spanned
2749–75791 nt. A 1700-bp EcoRI–XhoI human actin
DNA random primed probe was used to detect actin
RNA. Antisense RNA probes were prepared using a
romega Riboprobe kit. ORF50 riboprobe spanned the
omplement of 71596–71613 and 72570–72887. K8-59 ri-
oprobe spanned the complement of 74810–74930.
APDH hybridization was used to correct for variations
n RNA loading. The blot was incubated with the follow-
ng prehybridization solution for 5 h at 45°C: 53 standard
aline citrate (SSC), 7% SDS, 50 mM sodium phosphate,
H 7.0, 50% formamide, and 2% blocking reagent
oehringer-Mannheim). The probe was denatured by
ncubation at 80°C for 10 min and then was allowed to
ybridize to the membrane overnight at 45°C. The probe
as removed, and the blot was washed twice with 23
SC containing 0.1% SDS (15 min/wash) at room temper-
ture, followed by washing twice with 0.53 SSC contain-
ng 0.1% SDS (15 min/wash) at 65°C. Quantification of the
ranscripts was performed by phosphorimaging of the
lot (ImageQuant; Molecular Dynamics).
hemical treatments of cells and Northern blotting
BCBL-1 cells were treated with 20 nM TPA. For PAA
reatment, cells were incubated simultaneously with 20
M TPA and 100 mM PAA. For Cyc treatment, cells were
ncubated simultaneously with 20 nM TPA and 50 mg/ml
yc. Total RNA was isolated using Trizol reagent (GIBCO
RL) according to the manufacturer’s specifications. Ten
icrograms of total RNA from each sample was electro-
horesed on a 1% agarose gel containing 1% formalde-
yde. RNA was blotted to nylon membrane (Nytran;
chleicher & Schuell) using 103 SSC. The blot wasncubated with prehybridization solution (53 SSC, 50% cormamide, 50 mM sodium phosphate, pH 7.0, 7.0% SDS,
% Boehringer-Mannheim blocking reagent) at 65°C.
he blot was hybridized with riboprobes at 65°C in pre-
ybridization solution. The blot was washed twice with
3 SSC at room temperature and twice with 0.53 SSC at
5°C. Hybridized probes were detected by phosphor-
maging.
9 RACE
Poly(A)1 RNA was prepared as described above and
ubjected to a first-strand RT-PCR (Superscript) using an
ligo(dT) primer. The second-strand cDNA was made
sing a poly(T) oligomer and the 39 RACE primer (primer
0, ATCAGAGTCTATTCGCCC). The product was gel pu-
ified and cloned into pCRII vector. Sequencing of the
nsert was performed by automated sequencing (ABI 377).
T-PCR
RT-PCR was performed according to the manufactur-
r’s instructions (Superscript; GIBCO BRL). Primer sites
sed for these experiments are indicated in Fig. 2A.
rimer 46 was CCCAACTCTACCAGTGTGTGCT, and
rimer 49 was CGTGGAACGCACAGGTAAAG.
DNA library screening
Construction of the library in the ZAP express vector from
PA-stimulated BCP-1 cells and screening of the clones
ere performed according to the manufacturer’s protocol
Stratagene, La Jolla, CA). The inserts were sequenced by
utomated DNA sequencing (ABI 377 sequencer).
equencing
DNA was sequenced at the UNC-CH Automated DNA
equencing Facility on a model 377 DNA Sequencer
Perkin–Elmer, Applied Biosystems Division) using the
BI PRISMDye Terminator Cycle Sequencing Ready Re-
ction Kit with AmpliTaq DNA Polymerase, FS (Perkin–
lmer, Applied Biosystems Division)
reparation of nuclear and cytoplasmic extracts
BCBL-1 cells (5 3 106) were treated with TPA at a final
oncentration of 20 ng/ml in DMSO for 24, 48, and 72 h.
s a negative control, an equal amount of BCBL-1 cells
ere treated with an equal volume of DMSO only. After
reatment, BCBL-1 cells were washed twice with PBS
nd pelleted by centrifugation at 3000 g. Cells were
esuspended in buffer A (10 mM HEPES, pH 7.9, 1.5 mM
gCl2, 10 mM KCl, 1.0 mM dithiothreitol) and centrifuged
or 2 min at 4°C. The cells were gently resuspended in
uffer A containing 0.1% Nonidet P-40 and 2 mM phenyl-
ethylsulfonyl fluoride and incubated at 0°C for 10 min.
uclei were pelleted by centrifugation at 3000 g for 5 min
t 4°C. The supernatant was removed and saved as
ytoplasmic extract. The nuclear pellet was washed
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448 SEAMAN ET AL.nce with buffer A, and nuclei were pelleted by centrif-
gation at 3000 g for 5 min at 4°C. Nuclei were resus-
ended in buffer C (20 mM HEPES, pH 7.9, 0.42 M NaCl,
.5 mM MgCl2, 0.2 mM EDTA, 1 mM dithiothreitol, 25%
lycerol, 2 mM phenylmethylsulfonyl fluoride) and incu-
ated on ice for 30 min. Debris was removed by centrif-
gation at 12,000 g for 10 min at 4°C. The supernatant
as removed and used as nuclear extract. Protein con-
entration were determined by the Bradford assay.
estern blot analysis of ORF50 protein
Nuclear and cytoplasmic extracts from BCBL-1 cells
ere subjected to SDS–PAGE analysis. For each time-
oint, 10 mg of total nuclear protein and 50 mg of total
ytoplasmic protein were loaded on the gel. Proteins
ere transferred to nitrocellulose membranes using a
isher semidry blotting apparatus. Electroblotting was
erformed at 175 mA constant current for 30 min in
estern blotting buffer (20 mM Tris, 150 mM glycine, 20%
ethanol). After the transfer, the membrane was incu-
ated in 13 TBS (50 mM Tris, pH 7.5, 150 mM NaCl)
ontaining 0.05% Tween 20 and 1% blocking reagent
Boehringer-Mannheim) for 1 h. ORF50 protein was de-
ected by incubating the blot with a 1:1000 dilution of
abbit polyclonal anti-ORF50 antibody (gift of D. Ganem)
n 13 TBS. The blot was incubated with a 1:1000 dilution
f horseradish peroxidase-conjugated goat anti-rabbit
gG (Boehringer-Mannheim) in 13 TBS. Protein was de-
ected by ECL (Amersham) followed by autoradiography.
ransfections and CAT assays
Briefly, 107 cells were resuspended in 0.5 ml of RPMI
640. Total DNA (20 mg) was added, and cells were
lectroporated with a BioRad gene pulser. The capacitor
as charged to 950 F, and the cells received 0.25 V. After
lectroporation, the cells were resuspended in RPMI
640 and 10% FCS. The cells were incubated at 37°C for
8 h, and protein extraction and CAT assays were per-
ormed as previously described (Quinlivan et al., 1990).
eLa cells were transfected according to the method of
hen and Okayama (1987). Briefly, HeLa cells were
eeded onto 60-mm plates at 6.5 3 105 cells/plate 24 h
efore transfection. Then 0.5 ml of transfection cocktail
as prepared by combining 0.25 ml of 250 mM CaCl2
ith 0.25 ml of 23 BBS [50 mM N,N-bis(2-hydroxyethyl)-
-aminoethanesulfonic acid, 280 mM NaCl, 1.5 mM
a2PO4, pH 6.95]. Activator plasmid (3.5 mg) and reporter
lasmid (3.5 mg) were added to the transfection cocktail.
ells were overlaid with the transfection cocktail, fol-
owed by incubation for 20 h at 35°C in 3% CO2. Cells
ere washed twice with PBS, overlaid with DMEM
nd10% FCS, and incubated at 37°C in 5% CO2. At 48 h
fter the start of transfections, the cells were washed
wice with PBS and removed from the plates with a
ubber policeman. Cell pellets were obtained by centrif-gation at 3000 g for 5 min. Cells were suspended in 250
M Tris, pH 7.5. Lysates were prepared by three cycles
f freezing and thawing followed by centrifugation at
4,000 g for 5 min. Supernatants were recovered and
sed to determine CAT activity. Total protein was deter-
ined by the Bradford assay. Quantification was performed
y phosphorimaging (ImageQuant; Molecular Dynamics).
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